Myelin basic protein in the cerebrospinal fluid of patients with brain tumors.
We measured the level of myelin basic protein (MBP) in the cerebrospinal fluid (CSF) of patients with various kinds of tumors, including malignant tumors, using radioimmunoassay. The CSF had been obtained by lumbar puncture through an Ommaya reservoir or a shunt device placed in the lateral ventricle. The level of MBP was high (> 4 ng/ml) in the patients with meningeal dissemination of malignant tumors, but in those who showed a good response to chemotherapy and/or radiation, it decreased or returned to the normal level, with improvement on the computed tomography and magnetic resonance imaging, cytological, general CSF, and neurological findings. Of seven malignant gliomas without CSF dissemination, six showed an elevated level of MBP before selective intra-arterial chemotherapy with a combination of etoposide and cisplatin administered via a microcatheter placed at A1, M1, P1-P2, and the basilar top. All CSF specimens obtained during the period of the intra-arterial chemotherapy showed an abnormally high (> 4 ng/ml) level of MBP that exceeded the prechemotherapy level. The MBP level decreased or returned to normal in the patients with a good response to chemotherapy after intra-arterial chemotherapy. In some patients with multiple metastatic brain tumors, the MBP level was elevated before treatment and returned to normal after treatment (surgical removal, chemotherapy, and/or irradiation) in all except one. Thus, there was a clear correlation between the timing of treatment and changes in imaging studies and MBP levels.(ABSTRACT TRUNCATED AT 250 WORDS)
Nakagawa
H
H
Department of Neurosurgery, Center for Adult Diseases, Osaka, Japan.
Yamada
M
M
Kanayama
T
T
Tsuruzono
K
K
Miyawaki
Y
Y
Tokiyoshi
K
K
Hagiwara
Y
Y
Hayakawa
T
T
D000328:Adult; D000368:Aged; D001254:Astrocytoma / Q000134:cerebrospinal fluid / Q000175:diagnosis / Q000556:secondary / Q000628:therapy; D014408:Biomarkers, Tumor / Q000134:cerebrospinal fluid*; D001925:Brain Damage, Chronic / Q000134:cerebrospinal fluid / Q000175:diagnosis / Q000628:therapy; D001932:Brain Neoplasms / Q000134:cerebrospinal fluid* / Q000175:diagnosis / Q000556:secondary / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000134:cerebrospinal fluid / Q000175:diagnosis / Q000556:secondary / Q000628:therapy; D006801:Humans; D007261:Infusions, Intra-Arterial; D016393:Lymphoma, B-Cell / Q000134:cerebrospinal fluid / Q000175:diagnosis / Q000628:therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000134:cerebrospinal fluid / Q000175:diagnosis / Q000628:therapy; D008297:Male; D008577:Meningeal Neoplasms / Q000134:cerebrospinal fluid* / Q000175:diagnosis / Q000556:secondary / Q000628:therapy; D008579:Meningioma / Q000134:cerebrospinal fluid / Q000175:diagnosis / Q000556:secondary / Q000628:therapy; D008875:Middle Aged; D004676:Myelin Basic Protein / Q000134:cerebrospinal fluid*; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D004676:Myelin Basic Protein; D005047:Etoposide; D002945:Cisplatin